Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

Inclusion Criteria: * Patient has advanced idiopathic Parkinson's Disease associated chronic pain assessed by a Likert Pain Scale * Patient is taking Levodopa with a stable daily dose of at least 200 mg for at least 21 days prior to start * Hoehn and Yahr stage score of II to IV * Mini-Mental State Examination (MMSE) score ≥ 25 * If an antidepressant drug is taken, the dose must be stable for at least 21 days Exclusion Criteria: * Therapy with a Dopamine Agonist within 21 days prior to start * Discontinuation from previous Dopamine Agonist Therapy due to lack of efficacy * Therapy with Dopamine-modulating substances 21 days prior to start * Therapy with analgesics for the treatment for pain, unless the dose has been stable * Chronic alcohol or drug abuse * Medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the patient's ability to participate in this study * Hypersensitivity to any components of the Investigational Medicinal Product (IMP) or comparative drugs * Atypical Parkinson's Disease Syndrome due to drugs * History of deep brain stimulation * Significant skin disease that would make transdermal drug use inappropriate * Electroconvulsive therapy within 12 weeks prior to start * Evidence of an Impulse Control Disorder * Previous diagnosis of severe Restless Legs Syndrome * Chronic Migraine * Severe Depression * Symptomatic Orthostatic Hypotension